Neoadjuvant Anal Cancer VMAT: Lumbrosacral Plexus Dose Volume Histograms with Standard & Escalated Doses proposed in the ACT5 trial.

Elizabeth Findlay, Thuraiya Al-Hadjri , Lucy Wells, Leslie Samuel

Research output: Contribution to conferencePoster

Abstract

For the majority of patients, the LSP doses observed are well within those reported in the literature available. However the modelling does suggest that for patients with more advanced disease, often with more extensive pelvic nodal disease, who would be allocated higher treatment doses in ACT5, there may be clinical consequences. It would seem prudent to not only contour the LSP in these patients to know the radiation doses their LSP is receiving.
Original languageEnglish
DOIs
Publication statusPublished - 20 Apr 2018
EventEuropean Society for Therapeutic Radiotherapy & Oncology Annual Meeting - Barcelona, Spain
Duration: 20 Apr 201824 Apr 2018
Conference number: 37

Conference

ConferenceEuropean Society for Therapeutic Radiotherapy & Oncology Annual Meeting
Abbreviated titleESTRO 37
CountrySpain
CityBarcelona
Period20/04/1824/04/18

Keywords

  • lumbrosacral plexus
  • VMAT; dose volume histograms
  • ACT 5; anal cancer

Fingerprint Dive into the research topics of 'Neoadjuvant Anal Cancer VMAT: Lumbrosacral Plexus Dose Volume Histograms with Standard & Escalated Doses proposed in the ACT5 trial.'. Together they form a unique fingerprint.

  • Cite this

    Findlay, E., Al-Hadjri , T., Wells, L., & Samuel, L. (2018). Neoadjuvant Anal Cancer VMAT: Lumbrosacral Plexus Dose Volume Histograms with Standard & Escalated Doses proposed in the ACT5 trial.. Poster session presented at European Society for Therapeutic Radiotherapy & Oncology Annual Meeting, Barcelona, Spain. https://doi.org/10.3252/pso.eu.ESTRO37.2018